Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1982;23(2):93-7.
doi: 10.1007/BF00545961.

The clinical pharmacology of tolmesoxide. A new vasodilator antihypertensive agent

Clinical Trial

The clinical pharmacology of tolmesoxide. A new vasodilator antihypertensive agent

C P O'Boyle et al. Eur J Clin Pharmacol. 1982.

Abstract

The haemodynamic response and pharmacokinetics of single dose oral tolmesoxide were studied at various dose levels in 4 patients with severe hypertension. There was a reproducible fall in mean arterial pressure from baseline of 24.2% and a rise in heart rate of 37.6% following administration of tolmesoxide. The onset of antihypertensive action occurred within 1 h, with a peak effect at 3 h after dosing. The mean duration of action was up to 12.0 h. Tolmesoxide had a mean half-life of 3.0 h. It was rapidly absorbed with a mean peak plasma level occurring at 1.0 h. Plasma levels correlated well with the doses administered. Side-effects include mild nausea, facial flushing and postural symptoms.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Pharmacol. 1978 Oct;18(10):500-8 - PubMed
    1. Prog Cardiovasc Dis. 1974 Sep-Oct;17(2):99-113 - PubMed
    1. Circulation. 1953 Aug;8(2):199-204 - PubMed
    1. Br J Pharmacol. 1978 May;63(1):111-8 - PubMed
    1. Arch Intern Med. 1968 Nov;122(5):387-91 - PubMed

Publication types

LinkOut - more resources